Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering ... the aromatase inhibitors in patients with hormone receptor-positive MBC who have ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in ...

Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the ...

Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed a phase 3 trial in lymphoma ... alisertib has potential in hormone receptor-positive ...

It has now been 100 years since the first patient with diabetes received an injection of insulin, when Leonard Thomas, a 14-year-old boy, was treated with the hormone. The medical intervention was ...

Scientists explore how daily glucocorticoid signaling influences glioblastoma growth and synchronizes its circadian rhythms ...

The 1968 Treaty on the Non-Proliferation of Nuclear Weapons (NPT) is one of the most important and, with 191 signatory states, most comprehensive treaties of humankind. The NPT forms, together ...

Corticosteroids inhibit antigen presentation, cytokine production, and proliferation of lymphocytes ... are used to replace deficient endogenous hormones. In pharmacologic doses, corticosteroids ...

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) today announced that the first patient has been dosed in the Phase III ... acting growth hormone therapy and ...

HYOGO, Japan, December 20, 2024--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR") today announced that the first patient has been dosed in the Phase III clinical trial of JR-142 ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) today announced that the first patient has been dosed in the Phase III clinical ... JR-142 is a long-acting growth hormone therapy and is ...